Evidence map›Paper›PMID 28454069›Full record

ArticleRedox biology2017

CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP

David Leu, Ivan Spasojevic, Huy Nguyen, Brian Deng, Artak Tovmasyan, Tin Weitner, Romulo S Sampaio, Ines Batinic-Haberle, Ting-Ting Huang

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Balanced Duality: HInternational journal of molecular sciences · 2024
    Review
  6. Superoxide dismutase and neurological disorders.IBRO neuroscience reports · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. A Redox-active Mn Porphyrin, MnTnBuOE-2-PyPOxidative medicine and cellular longevity · 2022
    Article
  13. Article
  14. Article
  15. Catalytic Antioxidants in the Kidney.Antioxidants (Basel, Switzerland) · 2021
    Review
  16. HOxidative medicine and cellular longevity · 2021
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

David LeuDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.
Ivan SpasojevicDuke Cancer Institute, Pharmaceutical Research Shared Resource, PK/PD Core laboratory, Duke University Medical Center, Durham, NC, USA; Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Huy NguyenDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Brian DengDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Palo Alto Veterans Institute for Research, Palo Alto, CA, USA.
Artak TovmasyanDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Tin WeitnerDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Romulo S SampaioDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Ines Batinic-HaberleDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
Ting-Ting HuangDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Geriatric Research, Education, and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA.
Duke Medical Center · USStanford University · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

Although radiation therapy can be effective against cancer, potential damage to normal tissues limits the amount that can be safely administered. In central nervous system (CNS), radiation damage to normal tissues is presented, in part, as suppressed hippocampal neurogenesis and impaired cognitive functions. Mn porphyrin (MnP)-based redox active drugs have demonstrated differential effects on cancer and normal tissues in experimental animals that lead to protection of normal tissues and radio- and chemo-sensitization of cancers. To test the efficacy of MnPs in CNS radioprotection, we first examined the tissue levels of three different MnPs - MnTE-2-PyP

Indexed as

AnimalsBiological AvailabilityCentral Nervous SystemCerebral CortexCranial IrradiationFemaleHippocampusMaleMetalloporphyrinsMice, Inbred C57BLNeurogenesisOxidative StressRadiation-Protective Agentsmanganese (III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrinMetalloporphyrinsMn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrinMn(III) ortho-tetrakis(N-hexylpyridinium-2-yl)porphyrinRadiation-Protective AgentsBioavailabilityBMX-001HippocampusMn porphyrinNeurogenesisRadioprotection

Identifiers

PMID28454069
PMCPMC5407575
OpenAlexW2606736563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.